[D1-A2] Advances and Challenges in Bioanalysis of Oligonucleotide Therapeutics

1:25 PM - 1:50 PM JST(4:25 AM - 4:50 AM UTC)

[D1-A2-01] Development and Validation of LC–MS-Based Bioanalytical Methods for Oligonucleotide Therapeutics: Points to Consider

*Yuchen Sun¹, Shin-ichiro Nitta², Ryoya Goda³, Yuki Kishino⁴, Hisashi Fujita⁵, Masaaki Kakehi⁵, Yoshiharu Hayashi⁶, Satoshi Ito⁷, Tomomi Ishida⁸, Kiyomi Kikuchi⁸, Kazuko Inoue⁸, Kazutaka Shimbo⁹, Takeru Yamaguchi¹⁰, Fumihiro Jinno¹¹, Kaori Murakoshi¹², Kentaro Takahara¹³, Chie Murata¹⁴, Mitsuhiko Kawabata¹⁵, Kosuke Saito¹, Ruri Hanajiri¹, Yoshiro Saito¹ (1. National Institute of Health Sciences, 2. Mediford Corporation, 3. Future Peak Co., Ltd., 4. Daiichi Sankyo Co., Ltd., 5. Takeda Pharmaceutical Co., Ltd., 6. CMIC Pharma Science Co., Ltd., 7. Sekisui Medical Co., Ltd., 8. Eisai Co., Ltd., 9. Ajinomoto Co., Inc., 10. Sumika Chemical Analysis Service, Ltd., 11. Axcelead Drug Discovery Partners, Inc., 12. Tanabe Pharma Corporation, 13. Thermo Fisher Scientific K.K., 14. Ono Pharmaceutical Co., Ltd., 15. Shin Nippon Biomedical Laboratories, Ltd.)

Password required to view

Log in

or